Falcon Point Capital’s Clearside Biomedical CLSD Stock Holding History

Falcon Point Capital’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,081	Closed	-$192K	–	104
2018 Q3	$192K	Buy	2,081 +1,102	+113%	+$131K	0.04%	104
2018 Q2	$157K	Sell	979 -669	-41%	-$113K	0.03%	116
2018 Q1	$265K	Buy	1,648 +6	+0.4%	+$731	0.05%	104
2017 Q4	$172K	Sell	1,642 -1,306	-44%	-$140K	0.03%	115
2017 Q3	$315K	Buy	+2,948	New	+$360K	0.05%	102

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Falcon Point Capital's CLSD Position: Q4 2018 in Review

Falcon Point Capital sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 2,081 shares — an estimated $192K sold.

Falcon Point Capital first reported a position in CLSD in Q3 2017 and held it in 5 quarters. The position peaked at $315K in Q3 2017. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

Falcon Point Capital reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
Falcon Point Capital sold 2,081 Clearside Biomedical shares in Q4 2018, an estimated $192K.
Falcon Point Capital first reported a position in Clearside Biomedical in Q3 2017 and held it in 5 quarters.
Falcon Point Capital's Clearside Biomedical position peaked at $315K in Q3 2017.
69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Falcon Point Capital's 13F filing for Q4 2018, filed 31 Jan 2019.